Contemporary options and perspectives in the treatment of acromegaly
Authors:
Josef Marek
Authors‘ workplace:
III. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2014; 153: 131-136
Category:
Review Article
*Článek je věnován k 90. narozeninám prof. MUDr. Vratislava Schreibera, DrSc.
Overview
Acromegaly, if untreated, leads to numerous complications and premature death of patients. In recent years, significant changes in the treatment of acromegaly were achieved. The surgical approach was innovated, what allows completely selective removal of most microadenomas without any damage of the pituitary and safe debulking of the tumor mass in macroadenomas. Radiosurgery took the first place among irradiation methods, in our conditions it is the irradiation by the Leksell gamma knife. It allows selective irradiation of an adenoma without damaging the surrounding tissue. However, its effect on the secretory activity of the adenoma remains to be long lasting. Before this effect is attained, it is necessary to suppress the secretory activity pharmacologically. The infrequently effective, but economically advantageous and comfortable for patients is cabergoline, which is administered in tablet form. If cabergolin is not efficient, depot injections of somatostatin analogues – octreotide LAR and lanreotide autogel or their combination with cabergoline are used. The most efficient but financially costly is pegvisomant, blocking the receptors for growth hormone. In our conditions it is reserved for patients unresponsive to other treatments. With sufficient dosage it is possible to normalize hormonal activity of acromegly in 95 % of patients. New forms of the drugs as octreotide implants, oral octreotide octreolin or a new blocker of growth hormone receptors ATL-1103 are in the development.
Keywords:
acromegaly – Leksell gamma-knife – cabergoline – octreotide LAR – somatuline autogel – pegvisomant
Sources
1. Rajasoorya C, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 98–102.
2. Reid TJ, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 2010; 72: 203–208.
3. Vilar L, et al. Multiple facets in the control of acromegaly. Pituitary 2013; 17(Suppl 1) :11–17.
4. Melmed S, et al. Guidelines for acromegaly management: an update.J Clin Endocrinol Metab 2009; 94: 1509–1517.
5. Petrossians P, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152: 61–66.
6. Nomikos P, et al. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure. Eur J Endocrinol 2005; 152: 379–387.
7. Liščák R, et al. Stereotactic radiosurgery of pituitary adenomas. Neurosurg Clin N Am 2013; 24: 509–519.
8. Marek J, et al. Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 2011; 164: 169–178.
9. Leenstra JL, et al. Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 2010; 67: 27–32.
10. Ježková J, et al. Gamma knife radiosurgery for acromegaly – long term experience. Clin Endocrinol (Oxf) 2006; 64: 588–595.
11. Biermasz NR, et al. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 223–234.
12. Sandret L, et al. Place of cabergoline i n acromegaly: a meta-analysis.J Clin Endocrinol Metab 2011; 96: 1327–1335.
13. Abs R, et al. Cabergoline in the treatment of acromegaly, a study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374–378.
14. Murray RD, et al. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008; 93: 2957–2968.
15. Cuevas-Ramos D, et al. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 2014. Epub ahead of print.
16. Mercado M, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007; 66: 859–868.
17. Cozzi R, et al. Primary treatment of acromegaly with octreotide LAR: A long-term (up to nine years) prospective study of its tumor shrinkage.J Clin Endocrinol Metab 2006; 91: 1397–1403.
18. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 3013–3018.
19. Joseph S, et al. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy. Pancreas 2010; 39: 964–966.
20. Giustina A, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized controlled trial. Eur J Endocrinol 2008; 161: 331–338.
21. Sandret L, et al. Place of cabergoline in acromegaly: a meta-analysisJ Clin Endocrinol Metab 2011; 96: 1327–1335.
22. Petersenn S, et al. Long-term efficacy of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter Phase II extension study. Pituitary 2014; 17: 132–140.
23. Chieffo C, et al. Efficacy and safety on an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab 2013; 98: 4047–4054.
24. Tuvia S, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012; 97(7): 2362–2369. doi: 10.1210/jc.2012-1179. Epub 2012 Apr 26.
25. Van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754–1759.
26. Biering H, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatits. Eur J Endocrinol 2006; 154: 213–220.
27. Brue T. Acrostudy: Status update on 469 patients. Horm Res 2009; 71(Suppl 1): 34–38.
28. Van der Lely AJ, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011; 164: 325–333.
29. Giustina A, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Rev Endocrinol 2014; 10: 243–248.
30. Neggers SJ, et al. Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 2011; 164: 11–16.
31. Störmann S, et al. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2013; 19: 79–97.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Resisance to thyroid hormones
- Good death: Euthanasia in the eyes of medical students
- Contemporary possibilities of non-oral estrogen-progestin contraception
- Contemporary options and perspectives in the treatment of acromegaly